Skip to main content
Premium Trial:

Request an Annual Quote

Caris Dx to Buy Molecular Profiling Institute

NEW YORK (GenomeWeb News) - Caris Diagnostics has agreed to buy Molecular Profiling Institute for an undisclosed sum, Caris said yesterday.
 
Caris, which has a facility in Tempe, Ariz., said it expects to maintain that presence as well as MPI’s headquarters, which are located in Phoenix.
 
MPI is a reference lab that offers prognostic testing services and genomic and proteomic profiling for cancer and other complex diseases. Its proprietary offerings include Target Now, a late-stage cancer panel; Mammostrat, an early-stage breast cancer test; and CardioEvaluatR, which is a cardiovascular disease management panel.
 
MPI also has a Tissue Banking and Analysis Center offering biospecimen procurement, tracking, storage, analysis, and reporting for diagnostics and pharmaceutical companies and medical centers.
 
"Caris Diagnostics enhances our ability to provide more robust analysis, repository functions, and distribution to patients across the country," MPI CEO Robert Penny said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.